Mutations in the MYBPC3 gene encoding human cardiac myosin binding protein C (cMyBP-C) are associated with familial hypertrophic cardiomyopathy (FHC) but the molecular mechanisms involved are not fully understood. In addition, development of FHC is sensitive to genetic backgrounds and the search for candidate modifier genes is crucial with a view to proposing diagnosis and exploring new therapies. We used Drosophila as a model to investigate the in vivo consequences of human cMyBP-C mutations. We first produced transgenic flies that specifically express human wild type or two C-terminal truncated cMyBP-Cs in the Indirect Flight Muscles (IFM), a tissue particularly amenable to genetic and molecular analyses. Firstly, incorporation of human cMyBP-C in the IFM led to sarcomeric structural abnormalities and a flightless phenotype aggravated by age and gene dosage. FHC. In conclusion, we suggest that the combination of heterologous transgenesis and transcriptome analysis in Drosophila could be of great value as a way to glean insights into the molecular mechanisms underlying FHC and to propose potential candidate modifier genes.
Introduction
The ability to discover new susceptibility genes for human disorders depends on the description of the genetic pathways that are disturbed by mutations in disease-associated genes. With the achievement of genome sequencing programs and the development of functional genomics strategies, it is now possible to switch from the single gene approach to a genome-wide analysis and to obtain a description of a biological on the basis of a more extensive survey. Furthermore, analyses of similar molecular pathways in experimental model systems that are amenable to interdisciplinary functional studies are helpful in depicting the molecular processes involved in the disease and can provide insight into the disease gene functions. Interestingly, genetic pathways are highly conserved between human and fly.
Drosophila melanogaster shows 67% of similarity at the proteome level and approximately three quarters of human disease loci have their counterparts in the fruit fly (1) . Drosophila is actually a verified advantageous model for the study of complex human pathologies such as neurodegenerative diseases, diabetes, ageing or glaucoma (see (2) (3) (4) (5) respectively).
Concerning cardiomyopathies, Ferrùs et al (6) have already shown that Drosophila is a suitable experimental system for genetic screening for muscle protein interactions leading to suppressor identification that may provide new insights into heterogeneous diseases. The structural and functional molecular bases are highly conserved in all muscles of the phylum.
Sarcomeres are well organized structures showing a high degree of order and composed mostly of highly conserved proteins. Likewise, the physiological and molecular basis of the coupling between contraction and excitation is also conserved from invertebrates to vertebrates. The aim of this study was to assess the potential of Drosophila as a model organism to help unravel some aspects of the molecular mechanisms involved in Familial Hypertrophic Cardiomyopathy (FHC) development and provide a basis for proposing candidate modifiers genes.
FHC is a monogene disorder inherited in an autosomal-dominant fashion, for which mutations in at least 13 distinct genes, most of them encoding sarcomeric proteins, have been identified (7, 8) . More than 40% of the genotyped families carry a mutation in the MYBPC3 gene encoding cardiac myosin binding C protein (cMyBP-C; (9) ) and most mutations identified in MYBPC3 gene are predicted to produce C-terminal truncated proteins (10) . In addition, the phenotypic expression of FHC may be modulated by gene modifiers (reviewed in (7) ). The molecular bases of the hypertrophic response have not been fully elucidated partly because of the difficulty of accessing human cardiac tissue. However, in vitro and in at Pennsylvania State University on February 23, 2013 http://hmg.oxfordjournals.org/ Downloaded from 4 vivo studies have demonstrated that disruption of sarcomere structure and/or function may be a stimulus for hypertrophy (11). Other studies have implicated Ca 2+ as a primary signal for cardiac hypertrophy (12) . Recently, altered cardiac energetics has been proposed as a general mechanism underlying the phenotypic expression of FHC in both humans and mice (13, 14) .
Furthermore, cardiac hypertrophy is accompanied by modifications of gene expression such as reactivation of fetal gene programs, up-regulation of several growth factors and downregulation of adult forms of several cardiac genes, including the cardiac β-myosin heavy chain gene (15) . However, the cascade of molecular events leading to this switch has yet to be determined.
In the present study we have used a strategy involving three steps. First, a transheterologous approach to induce the expression of different forms of the human cMyBP-C in a specific Drosophila tissue. Second, the molecular consequences analysis of the cMyBP-C misexpression in a large scale perspective using the cDNA nylon microarray technology.
Third, the genetic validation of a candidate modifier gene, Calmodulin. The originality of our approach consists in using transcriptome analysis in order to select potential modifier genes which accelerate the discovery of genetic interactions necessary to resolve multigenic pathologies.
We used the in vivo UAS/GAL4 system (16), to express wild type or two truncated forms of cMyBP-C in the Drosophila Indirect Flight Muscles (IFM). IFM were chosen as the expression site rather than Drosophila heart mainly because of their experimental advantages (for review (6) . In particular, they fill a large part of the fly thorax and, therefore, constitute a material amenable to rapid and relatively easy structural and molecular analysis. Components of the contractile apparatus of striated muscle fibres are highly conserved in human;
moreover, IFM and cardiac muscles share common physiological properties (17) . IFM are asynchronous muscles whose contraction frequency is independent of nervous stimulation and they display stretch activation properties. IFM are also very sensitive to environmental and genetic backgrounds and slight disturbances of their structure and/or organisation lead to "flightless" flies, which are nonetheless viable and fertile. In the present study, we show that human cMyBP-C was readily incorporated into the IFM sarcomeres leading to structural and 
Results

Human cMyBP-C was targeted in Drosophila IFM
The human cMyBP-C protein is arranged in eight immunoglobulin-like C2-type (IgC2-like) domains and three fibronectin type-III (FN3) domains ( Figure 1 ) and shares the specific molecular architecture of the myosin-binding proteins family (18, 19) . No cMyBP-C homolog has been identified in the Drosophila genome (1). However, by a BLAST search of the entire bulk of Drosophila predicted proteins with cMyBP-C protein sequence, a fairly good homology score (P = 4.6 e-79) was obtained with Projectin protein, a member of the invertebrate titin-like family (20) . The best sequence alignment corresponds to 455 aminoacid of the human protein arranged in an Ig-FN3-FN3-Ig-FN3 repeated motif. Projectin contains a long repeated sequence composed of this motif, but only one occurrence, located at the N-terminal end of the Drosophila protein, was found to be homolog of the cMyBP-C protein (Fig 1a) . A reciprocal BLAST search of the collection of human reference proteins generated by the NCBI (21) with the 455 amino-acid Projectin domain produced best homology scores with 4 human titin isoforms (E = 1 e-73) and with cMyBP-C (E = 1 e-55).
The absence of a cMyBP-C counterpart in Drosophila genome ruled out considering the loss of function mutation approach and in consequence, a human cMyBP-C misexpression study was carried out. Using the UAS-GAL4 system (see Methods Section), transgenic flies were produced in which a full length wild type (WTt) or two C-terminal truncated forms of human cMyBP-C proteins (M6t and M0t, Figure 1b) were expressed in the IFM. The SG29.1-GAL4 driver used here induces expression during metamorphosis in the developing IFM, which is de novo built up during this stage (22) , and during the adult life. The human protein expressed with the aid of the UAS-GAL4 system was expected to be targeted to the sarcomere through unwarranted interactions with at least one specific endogenous sarcomeric 
Human cMyBP-C proteins expression in IFM led to flightless flies
The correct size and antigenicity of the expressed proteins were checked by Westernblot using an anti-Myc or an anti-cMyBP-C antibody. Within seven day old flies' IFM, the three human cMyBP-Cs appeared to be stably expressed and undegraded (data not shown). Furthermore, transgenic sarcomere lengths were found to be about 10% shorter on average than in SG29.1-GAL4 control flies ( Figure 5 ). In addition, our results suggest that M0t expression induced a more severe sarcomere length reduction when compared to WTt and M6t forms. Shorter sarcomeres observed under relaxing conditions might indicate a contracted state. The number of structural defects recovered within the transgenic sarcomeres increasing with age suggests a causal correlation between structural defects and inability to fly. The affected muscles would appear not to be able to execute any longer the contractionrelaxation cycles required for wing movement.
Transcriptional regulation in IFM was globally affected by transgenic human cMyBP-C expression
We next investigated whether the disarray of IFM myofibrillar structure and/or function induced by expression of human cMyBP-C correlatively results in remodelling of gene expression pattern using a preliminary large-scale trancriptome analysis. We . Surprisingly, overexpression of a human exogenous myofilament protein 9 able to incorporate into the IFM fibre is therefore accompanied by the coordinate downregulation of Drosophila genes encoding inter-related proteins.
Calmodulin is a modifier of the flightless phenotype
Differences in gene transcription might be related to the phenotype of transgenic flies (26) and deregulated genes could be potential modifiers. Among the deregulated genes, we found two genes encoding proteins involved in calcium signalling (Table 1 ). In particular, the 
Discussion
In this research we propose to use Drosophila as an in vivo system to investigate cardiomyopathies. Our aim was to assess the potential of this invertebrate model system by evaluating the structural, functional and molecular impact of the expression of human cMyBP-Cs proteins on the insect IFM. IFM is an ideal system for the expression of human protein.
In particular, the IFM structure and function are quite similar to that of the vertebrate striated muscles and most protein constituents have counterparts in both types of organisms.
Moreover, the high degree of order in the IFM makes it a sensitive indicator of alterations within the structure and the function of myofibrillar proteins.
Wild type and two C-terminal truncated cMyBP-C proteins have been driven in the IFM by means of the UAS-GAL4 system (16) . We show that in the fly the human cMyBP-Cs were incorporated into the sarcomere even though a human cMyBP-C counterpart was not In order to gain insights into the molecular mechanisms that underlie the human protein integration within the sarcomere architecture, a genomic approach has been adopted using cDNA microarray technology. We show that the expression of the human M0t cMyBP-C truncated form in the IFM triggered an overall transcriptional change. Likewise, several studies have shown that FHC are accompanied by a dramatic change in the global pattern of cardiac genes expression (15) . Among the 3570 Drosophila genes analysed using home made nylon cDNA microarrays, 97 were deregulated. This transcriptome study is currently being carried out with pan genome microarrays in order to evaluate the gene expression remodelling in function of age. However, the preliminary results obtained with the analysis of 25% of the predicted Drosophila genes, have already provided noteworthy information. In particular, we 12
show that the overexpression of cMyBP-C which leads to flightless phenotype is associated with the transcriptional down-regulation of 6 sarcomeric protein encoding genes.
The flightless phenotype could be due, at least in part, to the unbalance of the sarcomere proteins stoichiometry that is critical for muscle structure and/or function. Our analysis suggests that this disturbance is first transmitted at the transcriptional level and induces a coordinated down-regulation of genes encoding interrelated sarcomeric proteins. This type of cross-talk has already been mentioned in zebrafish mutant heart lacking Troponin T in which failure of sarcomere assembly was associated with down-regulation of at least Troponin I and Tropomyosin (40) . Likewise, mouse models of ablation and overexpression of myofilament genes in the heart suggest that transcriptional control may be one of the regulatory mechanisms involved in the regulation of myofilament protein stoichiometry (41, 42).
The negative co-regulation of the 6 Drosophila genes could have significant Experiments were carried out with pMT myc-tagged vector carrying different cMyBP-Cs (WT, M6t and M0t) described previously (45, 46) and cloned in the pUAST transformation vectors (16) .
Drosophila stocks
Germline transformation of y,w individuals was performed as previously described (47) . Among the 14 independent responder lines obtained for WT, M6t and M0t cMyBP-C transgenes, 6 were used in this study: UAS-WTt(6P5), UAS-M0t (7), UAS-M6t (13) (insertions on chromosome II) and UAS-WTt (6P3), UAS-M0t(2), UAS-M6t (9) 
Immunodetection
Flies were anaesthetized using CO 2 and then quickly beheaded. Thoraces were separated from the abdomen and carefully opened on ice (4°C) in relaxing buffer containing protease inhibitors (50% glycerol, 20 mM phosphate buffer, pH 7.0, 2 mM MgCl2, 1mM
EGTA, and 8mM DTT, 1mM PMSF, 0.2mM leupeptin, 5mM ATP) to avoid proteolysis and mechanical damage of the fibres that, in particular, might shorten them. Glycerol was eliminated by several washes with relaxing buffer (PBS, 5mM MgCl 2 , 1mM EGTA and 5mM ATP) without glycerol and all steps of the immunolabelling were performed in relaxing buffer.
IFM fibers were labelled using a monoclonal anti-myc antibody (9E10; Tebu-Bio).
Monoclonal IgG anti-Kettin Ig16 (MAC 155; (49) 
Electron microscopy
Hemi thoraces ultra-thin sections were prepared according to (50) and observed under a transmission LEO 912 electron microscope. Images were treated with digital scanner AGFA DUOSCAN.
Flight Test
Drosophila stocks were tested for flight ability in a cubic transparent Plexiglas box (100/100/100 cm) with a light source on the top part to encourage flies to fly. The flies were slightly anaesthetized using CO 2 and laid out in a beaker (20 cm height and 10 cm in diameter). The internal vertical surfaces were covered with aminopropyltriethoxysilane to prevent the flies from climbing. The container was stirred up every 5 min. Flies that were not able to leave the container within 20 min were considered as flightless.
Three lines were used as control for the flight tests: the SG29.1-GAL4 driver line reared at 29°C, the responder line bearing 2 copies of transgene reared at 29°C and the transgenic flies expressing 2 copies of M0t under the control of SG29.1 driver reared at 18°C. On average, a maximum of 2% of flightless flies were observed at day 18 for these control lines.
Statistical analysis
Flight test data are presented as average of two independent experiments and the difference between groups of data was assessed using log-rank test. Sarcomere length data are presented as mean ± SEM and analysed using Student's t-test. All results were considered as not significant (ns) when P>0.05, very significant when 0.01<P<0.05 (*) and extremely significant when P<0.001(**).
Total RNA extraction
Thoraces were prepared as described above and dissected immediately. 
